Utility of Contrast-Enhanced T2 FLAIR for Imaging Brain Metastases Using a Half-dose High-Relaxivity Contrast Agent

References

1. 1.↵
   1. Essig M,
   2. Knopp MV,
   3. Schoenberg SO, et al

   . Cerebral gliomas and metastases: assessment with contrast-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology 1999;210:551–57 doi:10.1148/radiology.210.2.r99ja22551 pmid:10207443

   CrossRefPubMed
2. 2.↵
   1. Aizer AA,
   2. Lee EQ

   . Brain metastases. Neurol Clin 2018;36:557–77 doi:10.1016/j.ncl.2018.04.010 pmid:30072071

   CrossRefPubMed
3. 3.↵
   1. Sorensen JB,
   2. Hansen HH,
   3. Hansen M, et al

   . Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988;6:1474–80 doi:10.1200/JCO.1988.6.9.1474 pmid:3047337

   Abstract/FREE Full Text
4. 4.↵
   1. Ahn SJ,
   2. Chung TS,
   3. Chang JH, et al

   . The added value of double dose gadolinium enhanced 3D T2 fluid-attenuated inversion recovery for evaluating small brain metastases. Yonsei Med J 2014;55:1231–37 doi:10.3349/ymj.2014.55.5.1231 pmid:25048479

   CrossRefPubMed
5. 5.↵
   1. Park J,
   2. Kim J,
   3. Yoo E, et al

   . Detection of small metastatic brain tumors: comparison of 3D contrast-enhanced whole-brain black-blood imaging and MP-RAGE imaging. Invest Radiol 2012;47:136–41 doi:10.1097/RLI.0b013e3182319704 pmid:22104961

   CrossRefPubMed
6. 6.↵
   1. Chang EL,
   2. Hassenbusch SJ 3rd.,
   3. Shiu AS, et al

   . The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases. Neurosurgery 2003;53:272–72 doi:10.1227/01.NEU.0000073546.61154.9A pmid:12925241

   CrossRefPubMed
7. 7.↵
   1. Park J,
   2. Kim EY

   . Contrast-enhanced, three-dimensional, whole-brain, black-blood imaging: application to small brain metastases. Magn Reson Med 2010;63:553–61 doi:10.1002/mrm.22261 pmid:20187162

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Kim D,
   2. Heo YJ,
   3. Jeong HW, et al

   . Usefulness of the delay alternating with nutation for tailored excitation pulse with T1-weighted sampling perfection with application-optimized contrasts using different flip angle evolution in the detection of cerebral metastases: comparison with MPRAGE. AJNR Am J Neuroradiol 2019;40:1469–75 doi:10.3174/ajnr.A6158 pmid:31371358

   Abstract/FREE Full Text
9. 9.↵
   1. Fahlstrom M,
   2. Fransson S,
   3. Blomquist E, et al

   . Dynamic contrast-enhanced magnetic resonance imaging may act as a biomarker for vascular damage in normal appearing brain tissue after radiotherapy in patients with glioblastoma. Acta Radiol Open 2018;7:2058460118808811 doi:10.1177/2058460118808811 pmid:30542625

   CrossRefPubMed
10. 10.↵
    1. Ozturk K,
    2. Soylu E,
    3. Tolunay S, et al

    . Dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging identifies glioblastoma immunohistochemical biomarkers via tumoral and peritumoral approach: a pilot study. World Neurosurg 2019;128:e195–208 doi:10.1016/j.wneu.2019.04.089 pmid:31003026

    CrossRefPubMed
11. 11.↵
    1. Mathews VP,
    2. King JC,
    3. Elster AD, et al

    . Cerebral infarction: effects of dose and magnetization transfer saturation at gadolinium-enhanced MR imaging. Radiology 1994;190:547–52 doi:10.1148/radiology.190.2.8284414 pmid:8284414

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Rogosnitzky M,
    2. Branch S

    . Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016;29:365–76 doi:10.1007/s10534-016-9931-7 pmid:27053146

    CrossRefPubMed
13. 13.↵
    1. Endrikat J,
    2. Dohanish S,
    3. Schleyer N, et al

    . 10 years of nephrogenic systemic fibrosis: a comprehensive analysis of nephrogenic systemic fibrosis reports received by a pharmaceutical company from 2006 to 2016. Invest Radiology 2018;53:541–50 doi:10.1097/RLI.0000000000000462 pmid:29547493

    CrossRefPubMed
14. 14.↵
    1. Tedeschi E,
    2. Caranci F,
    3. Giordano F, et al

    . Gadolinium retention in the body: what we know and what we can do. Radiol Med 2017;122:589–600 doi:10.1007/s11547-017-0757-3 pmid:28361260

    CrossRefPubMed
15. 15.↵
    1. Semelka RC,
    2. Ramalho J,
    3. Vakharia A, et al

    . Gadolinium deposition disease: initial description of a disease that has been around for a while. Magn Reson Imaging 2016;34:1383–90 doi:10.1016/j.mri.2016.07.016 pmid:27530966

    CrossRefPubMed
16. 16.↵
    1. Lord ML,
    2. Chettle DR,
    3. Grafe JL, et al

    . Observed deposition of gadolinium in bone using a new noninvasive in vivo biomedical device: results of a small pilot feasibility study. Radiology 2018;287:96–103 doi:10.1148/radiol.2017171161 pmid:29237148

    CrossRefPubMed
17. 17.↵
    1. Mathews VP,
    2. Caldemeyer KS,
    3. Lowe MJ, et al

    . Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology 1999;211:257–63 doi:10.1148/radiology.211.1.r99mr25257 pmid:10189481

    CrossRefPubMed
18. 18.↵
    1. Oguz KK,
    2. Cila A

    . Rim enhancement of meningiomas on fast FLAIR imaging. Neuroradiology 2003;45:78–81 doi:10.1007/s00234-002-0914-8 pmid:12592487

    CrossRefPubMed
19. 19.↵
    1. Terae S,
    2. Yoshida D,
    3. Kudo K, et al

    . Contrast-enhanced FLAIR imaging in combination with pre- and postcontrast magnetization transfer T1-weighted imaging: usefulness in the evaluation of brain metastases. J Magn Reson Imaging 2007;25:479–87 doi:10.1002/jmri.20847 pmid:17326092

    CrossRefPubMed
20. 20.↵
    1. Rumpel H,
    2. Chan LL

    . Serial FLAIR imaging after Gd-DTPA contrast: pitfalls in stroke trial magnetic resonance imaging. Stroke 2003;34:797–98 doi:10.1161/01.STR.0000056528.05390.58 pmid:12624311

    Abstract/FREE Full Text
21. 21.↵
    1. Mathews VP

    . Show me the gadolinium! AJNR Am J Neuroradiol 2005;26:440–41 pmid:15760846

    PubMed
22. 22.↵
    1. Ercan N,
    2. Gultekin S,
    3. Celik H, et al

    . Diagnostic value of contrast-enhanced fluid-attenuated inversion recovery MR imaging of intracranial metastases. AJNR Am J Neuroradiol 2004;25:761–65 pmid:15140715

    Abstract/FREE Full Text
23. 23.↵
    1. Kremer S,
    2. Abu Eid M,
    3. Bierry G, et al

    . Accuracy of delayed post-contrast FLAIR MR imaging for the diagnosis of leptomeningeal infectious or tumoral diseases. J Neuroradiol 2006;33:285–91 doi:10.1016/S0150-9861(06)77286-8 pmid:17213756

    CrossRefPubMed
24. 24.↵
    1. Vecht CJ,
    2. Haaxma-Reiche H,
    3. Noordijk EM, et al

    . Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33:583–90 doi:10.1002/ana.410330605 pmid:30125049

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Jackson EF,
    2. Hayman LA

    . Meningeal enhancement on fast FLAIR images. Radiology 2000;215:922–94 doi:10.1148/radiology.215.3.r00ap45922 pmid:10831726

    CrossRefPubMed
26. 26.↵
    1. Furutani K,
    2. Harada M,
    3. Mawlan M, et al

    . Difference in enhancement between spin echo and 3-dimensional fast spoiled gradient recalled acquisition in steady state magnetic resonance imaging of brain metastasis at 3-T magnetic resonance imaging. J Comput Assist Tomogr 2008;32:313–19 doi:10.1097/RCT.0b013e318074fd9d pmid:18379324

    CrossRefPubMed
27. 27.↵
    1. Lüdemann L,
    2. Grieger W,
    3. Wurm R, et al

    . Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn Reson Imaging 2005;23:833–41 doi:10.1016/j.mri.2005.06.007 pmid:16275421

    CrossRefPubMed
28. 28.↵
    1. Akeson P,
    2. Nordstrom CH,
    3. Holtas S

    . Time-dependency in brain lesion enhancement with gadodiamide injection. Acta Radiol 1997;38:19–24 doi:10.1080/02841859709171236 pmid:9059396

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Delattre JY,
    2. Krol G,
    3. Thaler HT, et al

    . Distribution of brain metastases. Arch Neurol 1988;45:741–44 doi:10.1001/archneur.1988.00520310047016 pmid:3390029

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Hasegawa H,
    2. Ushio Y,
    3. Hayakawa T, et al

    . Changes of the blood-brain barrier in experimental metastatic brain tumors. J Neurosurg 1983;59:304–10 doi:10.3171/jns.1983.59.2.0304 pmid:6864299

    CrossRefPubMed
31. 31.↵
    1. Yamada K,
    2. Ushio Y,
    3. Hayakawa T, et al

    . Quantitative autoradiographic measurements of blood-brain barrier permeability in the rat glioma model. J Neurosurg 1982;57:394–98 doi:10.3171/jns.1982.57.3.0394 pmid:7097336

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Blasberg RG,
    2. Kobayashi T,
    3. Patlak CS, et al

    . Regional blood flow, capillary permeability, and glucose utilization in two brain tumor models: preliminary observations and pharmacokinetic implications. Cancer Treat Rep 1981;65(Suppl 2)3–12 pmid:7346145

    PubMed
33. 33.↵
    1. Zagzag D,
    2. Hooper A,
    3. Friedlander DR, et al

    . In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 1999;159:391–400 doi:10.1006/exnr.1999.7162 pmid:10506510

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Fukumura D,
    2. Xu L,
    3. Chen Y, et al

    . Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001;61:6020–24 pmid:11507045

    Abstract/FREE Full Text
35. 35.↵
    1. Davis PL,
    2. Parker DL,
    3. Nelson JA, et al

    . Interactions of paramagnetic contrast agents and the spin echo pulse sequence. Invest Radiol 1988;23:381–88 doi:10.1097/00004424-198805000-00010 pmid:3384619

    CrossRefPubMed
36. 36.↵
    1. Park YW,
    2. Ahn SJ

    . Comparison of contrast-enhanced T2 FLAIR and 3D T1 black-blood fast spin-echo for detection of leptomeningeal metastases. Investig Magn Reson Imaging 2018;22:86 doi:10.13104/imri.2018.22.2.86

    CrossRef
37. 37.↵
    1. Akeson P,
    2. Larsson EM,
    3. Kristoffersen DT, et al

    . Brain metastases–comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 1995;36:300–06 doi:10.1177/028418519503600318 pmid:7742127

    CrossRefPubMed